{"id":"W3212987218","doi":"10.1016/j.ejca.2021.10.015","title":"Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Sanofi Genzyme; Cilag; Astellas Pharma; Genentech; UroGen Pharma; Boston Scientific Corporation; Array BioPharma; Invitae; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; Daiichi Sankyo Company; Ipsen; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Internal medicine; Oncology; Adverse effect; Post-hoc analysis; Subgroup analysis; Multivariate analysis; Cancer; Androgen receptor; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009870358,0.0009870031,0.00386859,0.000821804,0.000314752,0.0009447117,0.0006130306,0.0008471298,0.001872793],"category_scores_gemma":[0.005170261,0.0003449224,0.01337283,0.0009176229,0.0004757747,0.0005321699,0.0006750029,0.0007384116,0.0002073881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000600715,"about_ca_system_score_gemma":0.001170792,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00171243,"about_ca_topic_score_gemma":0.006717101,"domain_scores_codex":[0.9960227,0.002466423,0.0006178282,0.0004012934,0.0002713037,0.0002204617],"domain_scores_gemma":[0.9971591,0.001290478,0.0007498253,0.0004558298,0.0001812177,0.0001636254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7702335,0.0004384399,0.04687037,0.009118119,0.1323745,0.0002259636,0.0001690002,0.001769473,0.004893091,0.0002701548,0.001256918,0.03238041],"study_design_scores_gemma":[0.3518081,0.04907867,0.1951833,0.00167106,0.3852434,0.0007408496,0.00030478,0.002029626,0.00340316,0.001857746,0.00849788,0.0001813806],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9181738,0.06957263,0.001451059,0.0003968084,0.0003007539,0.002054609,0.005836142,0.00005795125,0.00215614],"genre_scores_gemma":[0.9868508,0.00647482,0.001328023,0.0003243213,0.0001604388,0.00104741,0.003054481,0.00001905075,0.0007405065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009870358,"threshold_uncertainty_score":0.05220008,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03063415493813856,"score_gpt":0.2966533057847531,"score_spread":0.2660191508466146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}